Design Therapeutics, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; comparable figures are for FY2021. The filing does not provide standalone fourth-quarter results in the supplied text.
Business context
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC small molecules for inherited nucleotide repeat expansion diseases. DT-216 for Friedreich ataxia (FA) was its only clinical-stage candidate at year-end; FECD and DM1 programs and other research programs remained preclinical or in discovery. The company had no approved products and generated no product-sales revenue.
Financial and operating performance
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $48.6 million | $24.8 million |
| General and administrative expense | $19.0 million | $11.1 million |
| Total operating expenses | $67.6 million | $35.8 million |
| Net loss | $63.3 million | $35.5 million |
| Net loss per share, basic and diluted | $1.14 | $0.77 |
| Net cash used in operating activities | $51.3 million | $29.4 million |
R&D growth reflected advancement of DT-216 into clinical development, investment in earlier programs, and higher personnel costs. G&A growth reflected increased staffing and public-company costs. Stock-based compensation was $10.9 million, up from $4.7 million. Operating margins are not meaningful because the company had no product revenue.
At December 31, 2022, cash and cash equivalents were $26.5 million and investment securities were $303.9 million, or $330.4 million combined, versus $384.1 million a year earlier. Current assets were $335.1 million and current liabilities $10.8 million. Total liabilities were $13.8 million, including lease liabilities; the filing reports no outstanding financial debt. Stockholders’ equity was $327.3 million. Available-for-sale securities had $3.4 million of gross unrealized losses, primarily attributed to interest-rate changes; no credit-loss allowance was recorded.
Material changes and developments
- Net loss increased by $27.8 million year over year; total operating expenses rose by $31.8 million.
- Operating cash use increased by $21.9 million. FY2022 investing cash use was $221.0 million, largely reflecting purchases of investment securities; financing cash flow was $0.2 million, compared with $379.2 million in FY2021, when the IPO and Series B financing generated proceeds.
- DT-216’s Phase 1 single-ascending-dose trial reported initial data in December 2022: generally well tolerated, with a greater-than-two-fold FXN mRNA increase in the highest-response cohort. No FXN protein increase was observed after a single dose in patient blood cells.
- DT-168 was nominated as a FECD development candidate in December 2022. The company reported preclinical activity and planned an IND submission in the second half of 2023. For DM1, it expected to complete IND-enabling studies and submit an IND in 2024.
Outlook, risks and unusual items
Management expected existing cash, cash equivalents and investments to fund planned operating expenses and capital needs for more than 12 months following the filing, but not to fund any candidate through regulatory approval. The company expects losses and expenses to increase as programs advance and anticipates needing substantial additional capital. Its effective shelf registration permits up to $300 million of securities, including a $100 million at-the-market program; no ATM shares had been sold by year-end 2022.
Key risks include clinical and regulatory uncertainty, limited human safety data, dependence on third-party manufacturers and research organizations, competition, intellectual-property protection, and future financing and dilution. In the SAD trial, three DT-216-treated patients experienced localized superficial vein thrombosis at the injection site; events were mild or moderate and self-limited. PK and PD data from the 200 mg cohort were excluded because of third-party sample-handling issues. The FDA approved omaveloxolone for certain FA patients on February 28, 2023, after the reporting period; the filing notes potential implications for future DT-216 trial enrollment and competition.
There were no material legal proceedings or contingent liabilities reported at year-end. Auditors issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective. The related-party office and laboratory leases and certain consulting arrangements are disclosed in the filing.
Important facts for investors to verify
- Progress, final data and safety profile of the ongoing DT-216 multiple-ascending-dose trial, including the significance of biomarker changes and injection-site events.
- Whether the anticipated DT-216 Phase 2 start and DT-168 IND submission timelines were achieved, and whether later development plans or costs changed.
- Cash runway assumptions, actual operating cash burn, and the timing and terms of any future financing or ATM issuance.
- Impact of omaveloxolone availability on FA trial enrollment, patient treatment choices and competitive positioning.
- Manufacturing and third-party execution risks, and the status and scope of patent protection and WARF license obligations.